Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07658105 eparlitozoviril Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658105, evaluating eparlitozoviril in Hepatocellular Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Recaticimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Recaticimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07657468 Docosahexaenoic acid Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07657468, evaluating Docosahexaenoic acid in Analgesia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Vunakizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Vunakizumab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
JPRN-jRCT2031260219 Cyclosporine Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260219, evaluating Cyclosporine in Coronary Artery Disease: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Desvenlafaxine Benzoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Desvenlafaxine Benzoate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07656909 Sirolimus Kaposiform Hemangioendothelioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07656909, evaluating Sirolimus in Kaposiform Hemangioendothelioma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07657273 Yttrium[90Y] carbosphere Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07657273, evaluating Yttrium[90Y] carbosphere in Hepatocellular Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Pancreatin/Ursodeoxycholic Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pancreatin/Ursodeoxycholic Acid: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
JPRN-jRCT2051260087 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2051260087, evaluating Rinatabart Sesutecan in Gastrointestinal Neoplasms: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Vitamin B2/Aspirin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Vitamin B2/Aspirin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07655661 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07655661, evaluating Tislelizumab in stomach adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.